

A.O. Ordine Mauriziano di Torino

Titolo:	A global, multicenter, randomized, double-blind, phase 3 pivotal registrational clinical study of APG-2575 (Lisafitoclax) combined with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia
Codice studio	GLORA3
Patologia:	Leucemia mieloide acuta
Tipo di Studio:	Interventistico
Tipologia	Profit
Fase:	3
Principali criteri di inclusione:	- newly diagnosed with de novo AML based on WHO 2022 Acute Myeloid Leukemia (AML) criteria, and be ineligible for standard chemotherapy (cytarabine and anthracyclines) due to the age or concomitant illness. - Creatinine clearance >30 mL/min
Principali criteri di esclusione:	- Patient diagnosed with acute promyelocytic leukemia (FAB classification of AML-M3 or WHO classification of APL with PML-RAR α or t (9; 22) (q34.1; q11.2); BCR-ABL1-positive AML patients). - Patient who has been previously treated (including chemotherapy, targeted drugs, monoclonal antibodies and investigational drugs, excluding supportive treatments and hydroxycarbamide) for hematologic disorders, such as AML or MDS
Struttura	SCDU Ematologia e Terapie Cellulari
Contatto	Prof.ssa Daniela Cilloni daniela.cilloni@unito.it